- Home
- AACG vs CALC Comparison
AACG vs CALC Comparison
Compare AACG & CALC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AACG
- CALC
- Stock Information
- Founded
- AACG 1999
- CALC 2011
- Country
- AACG China
- CALC United States
- Employees
- AACG N/A
- CALC N/A
- Industry
- AACG Other Consumer Services
- CALC Biotechnology: Pharmaceutical Preparations
- Sector
- AACG Real Estate
- CALC Health Care
- Exchange
- AACG Nasdaq
- CALC Nasdaq
- Market Cap
- AACG 27.1M
- CALC 26.7M
- IPO Year
- AACG N/A
- CALC N/A
- Fundamental
- Price
- AACG $0.80
- CALC $1.68
- Analyst Decision
- AACG
- CALC Strong Buy
- Analyst Count
- AACG 0
- CALC 3
- Target Price
- AACG N/A
- CALC $16.33
- AVG Volume (30 Days)
- AACG 14.6K
- CALC 24.2K
- Earning Date
- AACG 05-16-2025
- CALC 05-14-2025
- Dividend Yield
- AACG N/A
- CALC N/A
- EPS Growth
- AACG N/A
- CALC N/A
- EPS
- AACG N/A
- CALC N/A
- Revenue
- AACG $37,997,003.00
- CALC N/A
- Revenue This Year
- AACG N/A
- CALC N/A
- Revenue Next Year
- AACG N/A
- CALC N/A
- P/E Ratio
- AACG N/A
- CALC N/A
- Revenue Growth
- AACG 21.24
- CALC N/A
- 52 Week Low
- AACG $0.50
- CALC $1.43
- 52 Week High
- AACG $1.10
- CALC $5.97
- Technical
- Relative Strength Index (RSI)
- AACG 32.15
- CALC 43.11
- Support Level
- AACG $0.87
- CALC $1.61
- Resistance Level
- AACG $0.92
- CALC $1.73
- Average True Range (ATR)
- AACG 0.04
- CALC 0.10
- MACD
- AACG -0.01
- CALC -0.02
- Stochastic Oscillator
- AACG 0.06
- CALC 16.26
About AACG ATA Creativity Global
ATA Creativity Global is an international educational services company focused on providing quality learning experiences that cultivate and enhance students' creativity. The operating segments are Overseas art study services, Other educational services and K-12 education assessment and other services. Majority of its revenue comes from Overseas art study services.
About CALC CalciMedica Inc.
CalciMedica Inc is a clinical-stage biopharmaceutical company focused on developing therapeutics that treat serious illnesses driven by inflammatory and immunologic processes and direct cellular damage. Its product candidates act upon calcium release-activated calcium (CRAC) channels and would constitute a new class of drugs. Its product candidate is Auxora, a potent and selective intravenous formulated small molecule CRAC channel inhibitor containing the active compound zegocractin (formerly referred to as CM4620) that, in animal models, reduced acute epithelial and/or endothelial cell injury and inflammation in organs, such as the pancreas, lungs and kidneys.